ScholarIQanswers from OpenAlex
Tennessee Oncology
InstitutionResearch output, impact & collaborations
Tennessee Oncology is a institution indexed in ScholarIQ from OpenAlex.
What is known about Tennessee Oncology?
ScholarIQrecord summary
Tennessee Oncology is a research organisation in Nashville, US. OpenAlex records 3,841 works and 371,118 citations for it. 539 researchers list it as their most recent affiliation.
How many works does Tennessee Oncology have?
ScholarIQindexed works
Tennessee Oncology has 3,841 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Tennessee Oncology have?
ScholarIQcitation count
Tennessee Oncology has 371,118 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Tennessee Oncology?
ScholarIQresearcher count
Tennessee Oncology has 539 researchers in the ScholarIQ index.
What is the average h-index at Tennessee Oncology?
ScholarIQavg h-index
Tennessee Oncology has an average h-index of 91.5 in OpenAlex.
What is the ROR of Tennessee Oncology?
ScholarIQror
The ROR for Tennessee Oncology is on the source record.
What is the OpenAlex record for Tennessee Oncology?
ScholarIQopenalex
The OpenAlex for Tennessee Oncology is on the source record.
Who are the most-cited researchers behind Tennessee Oncology?
ScholarIQtop researchers by citations
What are the most-cited papers on Tennessee Oncology?
ScholarIQmost cited works
Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation
Navneet S. Majhail, Stephanie Farnia, Paul A. Carpenter, Richard E. Champlin, Stephen W. Crawford, David I. Marks, James Omel, Paul J. Orchard, Jeanne Palmer, Wael Saber, Bipin N. Savani, Paul Veys, Christopher Bredeson, Sergio Giralt, C. Frederick LeMaistre
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Franck Morschhauser, Nathan Fowler, Pierre Feugier, Réda Bouabdallah, Hervé Tilly, M. Lia Palomba, Christophe Fruchart, Edward N. Libby, Olivier Casasnovas, Ian W. Flinn, Corinne Haïoun, Hervé Maisonneuve, Loïc Ysebaert, Nancy L. Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Nicolas Daguindau, Steven Le Gouill, Gian M. Pica, Alejandro Martı́n, Armando López‐Guillermo, Jean-François Larouche, Kiyoshi Ando, María Gomes da Silva, Marc André, Pierre Zachée, Laurie H. Sehn, Kensei Tobinai, Guillaume Cartron, David Liu, Jianming Wang, Luc Xerri, Gilles Salles
Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles, Sarit Assouline, Laurie H. Sehn, Ian W. Flinn, Manish R. Patel, Randeep Sangha, Anton Hagenbeek, Ranjana H. Advani, Hervé Tilly, Olivier Casasnovas, Oliver W. Press, Sreeni Yalamanchili, Robert S. Kahn, Randall Dere, Dan Lü, Surai Jones, Cheryl Jones, Yu-Waye Chu, Franck Morschhauser
Secondary solid cancer screening following hematopoietic cell transplantation
Yoshihiro Inamoto, Nirali N. Shah, Bipin N. Savani, Bronwen E. Shaw, Allistair Abraham, Ibrahim Ahmed, Görgün Akpek, Yoshiko Atsuta, K. Scott Baker, Grzegorz Basak, Menachem Bitan, Zachariah DeFilipp, Tara Gregory, Hildegard Greinix, Mehdi Hamadani, Betty K. Hamilton, Robert J. Hayashi, David A. Jacobsohn, Rammurti T. Kamble, Kimberly A. Kasow, Nandita Khera, Hillard M. Lazarus, Adriana K. Malone, Maria Teresa Lupo Stanghellini, Steven Margossian, Lori Muffly, Maxim Norkin, Muthalagu Ramanathan, Nina Salooja, Hélène Schoemans, John R. Wingard, Baldeep Wirk, William A. Wood, Agnes S. M. Yong, C. Duncan, Mary E.D. Flowers, Navneet S. Majhail
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
David P. Steensma, Martin Wermke, Virginia M. Klimek, Peter L. Greenberg, Patricia Font, Rami S. Komrokji, Jay Yang, Andrew M. Brunner, Hetty E. Carraway, Lionel Adès, Aref Al‐Kali, Juan Manuel Alonso‐Domínguez, Ana Alfonso Piérola, Catherine C. Coombs, H. Joachim Deeg, Ian W. Flinn, James M. Foran, Guillermo Garcia‐Manero, Michael B. Maris, Malgorzata McMasters, Jean‐Baptiste Micol, Jaime Pérez de Oteyza, Felicitas Thol, Eunice S. Wang, Justin M. Watts, Justin Taylor, Richard M. Stone, Vikram Gourineni, Alyssa J. Marino, Huilan Yao, Benoit Destenaves, Xiaobin Yuan, Kun Yu, Sara Dar, Lernik Ohanjanian, Keisuke Kuida, Jianjun Xiao, Catherine Scholz, Antonio Gualberto, Uwe Platzbecker
How much of the research on Tennessee Oncology is open access?
ScholarIQopen access share
71%OPEN ACCESS